Jean-Luc Lowinski appointed CEO of Pierre Fabre Médicament
April 15, 2019
Castres, April 15, 2019 – The Pierre Fabre Group is pleased to announce the appointment of Jean-Luc Lowinski to the role of CEO of Pierre Fabre Pharmaceuticals, the Group's pharmaceuticals division (PFM). He assumed his new position on April 1, 2019 and also sits on the Group’s Executive Committee.
Jean-Luc Lowinski, 54, is a veterinarian and holds an MBA from INSEAD. From 1992 to 2012, he pursued his career at Bayer, working primarily abroad--in Japan, South Korea, Singapore, India, Thailand, and China--in the Healthcare and Consumer Care pharmaceutical divisions. In 2012, he joined the Sanofi group, serving at the Shanghai offices as Vice President, Asia--a €2 billion business with a workforce of 10,000 people. Since 2017, he had been Vice President of Emerging Markets at Sanofi Genzyme.
At Pierre Fabre, he is in charge of developing the pharmaceutical activities: oncology, prescription drugs and consumer health care (the Pierre Fabre Health Care, Pierre Fabre Oral Care, and Naturactive franchises). The pharmaceutical division generated €880 million in revenues in 2018, of which 57% was achieved via 29 subsidiaries. The division employs some 6,000 people.
About Pierre Fabre:
With a portfolio representing a continuum of activities spanning from prescription drugs and consumer healthcare products to dermo-cosmetics, Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world, the 2nd largest private French pharmaceutical group and the market leader in France for products sold over the counter in pharmacies. Its portfolio includes several global brands and franchises among which Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma, Galénic, Elancyl, Naturactive, Pierre Fabre Health Care, Pierre Fabre Oral Care, Pierre Fabre Dermatologie and Pierre Fabre Oncologie. In 2018, Pierre Fabre generated 2,326 million euros in revenues, of which 63% came from its international business and 61% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, counts about 11,000 employees worldwide, owns subsidiaries and offices in 47 countries and enjoys distribution agreements in over 130 countries. In 2018, Pierre Fabre dedicated 187 million euros to R&D efforts, split between oncology, consumer healthcare, dermatology and dermo-cosmetics. Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a governmentrecognized public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan.
The independent French certification group AFNOR audited in 2015 Pierre Fabre for its corporate social responsibility policy at the “exemplary” level, according to the ISO 26000 standard for CSR.